{"id":2810,"date":"2023-09-06T09:56:49","date_gmt":"2023-09-06T09:56:49","guid":{"rendered":"https:\/\/mlnews.dev\/?p=2810"},"modified":"2023-10-02T05:10:08","modified_gmt":"2023-10-02T05:10:08","slug":"ais-covid-19-wonder-drug","status":"publish","type":"post","link":"https:\/\/mlnews.dev\/ais-covid-19-wonder-drug\/","title":{"rendered":"AI’s COVID-19 Wonder Drug: Phase I Trials Underway"},"content":{"rendered":"\n
Insilico Medicine, a biotech company using artificial intelligence (AI), has started Phase I clinical trials for an AI’s COVID-19 treatment, marking a significant development in healthcare. Unlike vaccines, this oral drug, called ISM3312, aims to treat COVID symptoms. If approved, it would offer an alternative to Paxlovid, the current medication with reported side effects like “Paxlovid rebound” and an unpleasant taste. ISM3312 has shown effectiveness against Paxlovid-resistant variants, is more stable, and has a longer-lasting impact. Clinical trial results are expected by the end of 2023, although caution and further trials are emphasized to confirm its safety and effectiveness.<\/p>\n\n\n